Raloxifene 60mg 100 tablets


Raloxifene selectively binds to estrogen receptors in the body, exhibiting estrogenic and anti-estrogenic activities depending on the target tissues. In bones, it maintains bone density and reduces bone turnover, helping to mitigate the risk of fractures—a significant concern post-menopause. Conversely, it counteracts the effects of estrogen on the breast and uterine tissues, thus presenting a protective effect against certain forms of cancer associated with high estrogen levels. This distinctive dual action makes raloxifene a cornerstone drug for many women navigating the postmenopausal period.



Raloxifene, marketed under the brand name Evista among others, is a selective estrogen receptor modulator (SERM) renowned for its efficacy in treating and preventing osteoporosis in postmenopausal women. It also plays a pivotal role in reducing the risk of invasive breast cancer in postmenopausal women who are at high risk or have osteoporosis. By mimicking the bone-protective effects of estrogen without its potentially adverse impact on the breast and uterus, raloxifene represents a finely-tuned intervention in hormonal therapy.

Additional information



●Prevention and treatment of osteoporosis in postmenopausal women help strengthen bone mineral density and lower the incidence of vertebral fractures.

●Risk reduction of invasive breast cancer in postmenopausal women with osteoporosis and high-risk postmenopausal women.

Administration Guidelines

Oral Administration:

●Raloxifene is administered orally with or without meals. The recommended dosage typically consists of a daily 60 mg tablet, although varying dosages may be prescribed based on the patient's medical condition, response to treatment, and the prescribing doctor's judgment.

Dosage Forms:

●60 mg oral tablets are typically prescribed to be taken once daily. Consistency in the time of day taken may enhance the medication's efficacy and stability of therapeutic effects.

Safety Preclusions

Pregnancy and Breastfeeding:

●Raloxifene is contraindicated during pregnancy and breastfeeding. It falls under FDA pregnancy category X, indicating that it can harm the fetus and therefore should not be used during pregnancy. Similarly, it should not be administered to nursing mothers to prevent adverse effects on the infant.

Long-term Use:

●Long-term use of raloxifene requires careful monitoring of the patient’s health, including regular assessments of bone mineral density and comprehensive evaluations of the potential risks of prolonged therapy, such as blood clots and stroke.

Drug Interactions:

●Raloxifene should be used cautiously with other medications, particularly those known to affect blood clotting such as warfarin, as well as other hormone replacement therapies and supplements like black cohosh which might alter its effects.

Side Effects:

●Hot flashes
●Leg cramps
●Flu-like symptoms
●Joint pain

Serious Side Effects:

●Increased risk of venous thromboembolism
●Pulmonary embolism
●Retinal vein thrombosis


To maintain its effectiveness, store raloxifene at room temperature, away from excessive heat and moisture. Keeping the medication in its original packaging until use is essential to protect it from environmental factors and ensure child safety.

Special Precaution

Patients are advised to stand up slowly from a seated or lying position to avoid the risk of orthostatic hypotension. Women with a history of blood clots or stroke should discuss the potential risks and benefits of raloxifene with their healthcare provider.


Symptoms of raloxifene overdose may include leg cramps and dizziness. In cases of suspected overdose, prompt medical intervention is required to manage symptoms effectively and mitigate any potential risks.


There are no reviews yet.

Be the first to review “Raloxifene 60mg 100 tablets”

Your email address will not be published. Required fields are marked *